ANTX - AN2 Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ANTX is currently covered by 5 analysts with an average price target of $5.32. This is a potential upside of $4.23 (388.07%) from yesterday's end of day stock price of $1.09.

AN2 Therapeutics's activity chart (see below) currently has 2 price targets and 19 ratings on display. The stock rating distribution of ANTX is 56.25% BUY and 43.75% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 20.83% with an average time for these price targets to be met of 67.25 days.

Highest price target for ANTX is $3, Lowest price target is $3, average price target is $5.32.

Most recent stock forecast was given by LIISA BAYKO from EVERCORE on 09-Aug-2024. First documented stock forecast 19-Apr-2022.

Best performing analysts who are covering ANTX - AN2 Therapeutics:

Kevin Degeeter Joseph Schwartz Liisa Bayko Roy Buchanan

Currently out of the existing stock ratings of ANTX, 9 are a BUY (56.25%), 7 are a HOLD (43.75%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

$2

2 months 27 days ago
(09-Aug-2024)

1/3 (33.33%)

$-0.27 (-11.89%)

15

Buy

$3

$1.92 (177.78%)

2 months 27 days ago
(09-Aug-2024)

0/2 (0%)

$1.97 (191.26%)

Hold

$7

4 months 2 days ago
(03-Jul-2024)

0/2 (0%)

$3.1 (79.49%)

Buy

$27

$25.92 (2400.00%)

$24

1 years 1 months 23 days ago
(13-Sep-2023)

2/4 (50%)

$12.12 (81.45%)

254

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ANTX (AN2 Therapeutics) average time for price targets to be met?

On average it took 67.25 days on average for the stock forecasts to be realized with a an average price target met ratio 20.83

Which analyst has the current highest performing score on ANTX (AN2 Therapeutics) with a proven track record?

KEVIN DEGEETER

Which analyst has the current lower performing score on ANTX (AN2 Therapeutics) with a proven track record?

ROY BUCHANAN

Which analyst has the most public recommendations on ANTX (AN2 Therapeutics)?

Kevin Degeeter has 7 price targets and 6 ratings on ANTX

Which analyst is the currently most bullish on ANTX (AN2 Therapeutics)?

Kevin Degeeter with highest potential upside - $25.92

Which analyst is the currently most reserved on ANTX (AN2 Therapeutics)?

Joseph Schwartz with lowest potential downside - -$0

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?